4D-150 shows significant reduction in injection burden for wet AMD, with promising durability and tolerability in ongoing clinical trials. 4D Molecular Therapeutics has released positive interim ...
The MarketWatch News Department was not involved in the creation of this content. -- 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level -- ...
Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) are currently up over 20.6% after the company released positive results from its Spectra trial. The Spectra trial evaluates 4D-150 in patients with ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients treated with the gene therapy maintained visual ...
(RTTNews) - Shares of 4D Molecular Therapeutics (FDMT) are up over 26% to $5.69 in premarket trading Friday, following positive 60-week data from its Phase II SPECTRA trial. The SPECTRA trial is ...
Initial interim landmark data analysis (N=50 at 24 Weeks) to be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial ...
On Saturday, 4D Molecular Therapeutics (NASDAQ:FDMT) announced initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM trial of 4D-150 in a broad wet age-related ...
4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback